ARDX Ardelyx Inc.

2.15
-0.04  -2%
Previous Close 2.19
Open 2.12
Price To Book 0.94
Market Cap 133589240
Shares 62,134,530
Volume 387,855
Short Ratio
Av. Daily Volume 276,402

SEC filingsSee all SEC filings

  1. 8-K - Current report 181166280
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166240
  3. 8-K - Current report 181006709
  4. 424B5 - Prospectus [Rule 424(b)(5)] 181006488
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 18998479

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date September 13, 2019.
Tenapanor (T3MPO-2)
Constipation-predominant irritable bowel syndrome (IBS-C)
Onset of action trial data released November 21, 2017 - noted significantly reduced serum potassium in patients. Development to be discontinued.
RDX7675
Hyperkalemia
Phase 3 released February 15, 2017 - primary endpoint met. Data from second Phase 3 trial due 2019.
Tenapanor
Hyperphosphatemia in end-stage renal disease (ESRD) patients
Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.
Tenapanor (T3MPO-1)
Constipation-predominant irritable bowel syndrome (IBS-C)

Latest News

  1. What Type Of Shareholder Owns Ardelyx Inc’s (NASDAQ:ARDX)?
  2. Ardelyx Announces FDA Acceptance of the Filing of its New Drug Application for Tenapanor for the Treatment of Patients with IBS-C
  3. Ardelyx: 3Q Earnings Snapshot
  4. Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights
  5. Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus
  6. Analysis: Positioning to Benefit within Ardelyx, AXT, TG Therapeutics, MarineMax, Oclaro, and BioCryst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
  7. Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting
  8. Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders
  9. How Does Investing In Ardelyx Inc (NASDAQ:ARDX) Impact Your Portfolio?
  10. Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration
  11. Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
  12. Edited Transcript of ARDX earnings conference call or presentation 7-Aug-18 8:30pm GMT
  13. Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights
  14. Ardelyx, Inc. to Host Earnings Call
  15. Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call
  16. Free Technical Reports on Array BioPharma and Three Additional Biotech Equities
  17. Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference

SEC Filings

  1. 8-K - Current report 181166280
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166240
  3. 8-K - Current report 181006709
  4. 424B5 - Prospectus [Rule 424(b)(5)] 181006488
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 18998479
  6. 8-K - Current report 18998073
  7. SC 13G - Statement of acquisition of beneficial ownership by individuals 18962125
  8. 8-K - Current report 18943319
  9. 8-K - Current report 18899887
  10. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 18888796